110 related articles for article (PubMed ID: 18305181)
1. Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival.
Milne AN; Carvalho R; Jansen M; Kranenbarg EK; van de Velde CJ; Morsink FM; Musler AR; Weterman MA; Offerhaus GJ
J Clin Pathol; 2008 Mar; 61(3):311-6. PubMed ID: 18305181
[TBL] [Abstract][Full Text] [Related]
2. A study of the expression of Cyclin E and its isoforms in tumor and adjacent mucosa, correlated to patient outcome in early colon cancer.
Corin I; Larsson L; Bergström J; Gustavsson B; Derwinger K
Acta Oncol; 2010; 49(1):63-9. PubMed ID: 20001501
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer.
Zhou YJ; Xie YT; Gu J; Yan L; Guan GX; Liu X
Eur J Surg Oncol; 2011 Dec; 37(12):1078-84. PubMed ID: 21944050
[TBL] [Abstract][Full Text] [Related]
4. Cyclin E and survival in patients with breast cancer.
Keyomarsi K; Tucker SL; Buchholz TA; Callister M; Ding Y; Hortobagyi GN; Bedrosian I; Knickerbocker C; Toyofuku W; Lowe M; Herliczek TW; Bacus SS
N Engl J Med; 2002 Nov; 347(20):1566-75. PubMed ID: 12432043
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
[TBL] [Abstract][Full Text] [Related]
7. Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer.
Spruck C; Sun D; Fiegl H; Marth C; Mueller-Holzner E; Goebel G; Widschwendter M; Reed SI
Cancer Res; 2006 Jul; 66(14):7355-60. PubMed ID: 16849587
[TBL] [Abstract][Full Text] [Related]
8. Why are the truncated cyclin Es more effective CDK2 activators than the full-length isoforms?
Rath SL; Senapati S
Biochemistry; 2014 Jul; 53(28):4612-24. PubMed ID: 24947816
[TBL] [Abstract][Full Text] [Related]
9. Processing of cyclin E differs between normal and tumor breast cells.
Harwell RM; Porter DC; Danes C; Keyomarsi K
Cancer Res; 2000 Jan; 60(2):481-9. PubMed ID: 10667604
[TBL] [Abstract][Full Text] [Related]
10. Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression.
Choi MG; Noh JH; An JY; Hong SK; Park SB; Baik YH; Kim KM; Sohn TS; Kim S
J Surg Res; 2009 Dec; 157(2):168-74. PubMed ID: 19559447
[TBL] [Abstract][Full Text] [Related]
11. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
Voduc D; Nielsen TO; Cheang MC; Foulkes WD
Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
[TBL] [Abstract][Full Text] [Related]
12. Small interference RNA-mediated suppression of overexpressed cyclin E protein restores G1/S regulation in NIH-OVCAR-3 ovarian cancer cells.
Todd MC; Spruill SC; Meerbrey KL
Int J Oncol; 2009 Aug; 35(2):375-80. PubMed ID: 19578752
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle dysregulation influences survival in high risk breast cancer patients.
Königsberg R; Rögelsperger O; Jäger W; Thalhammer T; Klimpfinger M; De Santis M; Hudec M; Dittrich C
Cancer Invest; 2008 Aug; 26(7):734-40. PubMed ID: 18665474
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of cell cycle-related molecules in gastric carcinoma: prognostic significance, correlation with clinicopathological parameters, proliferation and apoptosis.
Lee KH; Lee HE; Cho SJ; Cho YJ; Lee HS; Kim JH; Nam SY; Chang MS; Kim WH; Lee BL
Pathobiology; 2008; 75(6):364-72. PubMed ID: 19096232
[TBL] [Abstract][Full Text] [Related]
15. Elevated cyclin E level in human clear cell renal cell carcinoma: possible causes and consequences.
Nauman A; Turowska O; Poplawski P; Master A; Tanski Z; Puzianowska-Kuznicka M
Acta Biochim Pol; 2007; 54(3):595-602. PubMed ID: 17726548
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of cyclin E expression in operable breast cancer.
Potemski P; Kusińska R; Pasz-Walczak G; Piekarski JH; Watała C; Płuciennik E; Bednarek AK; Kordek R
Med Sci Monit; 2009 Feb; 15(2):MT34-40. PubMed ID: 19179977
[TBL] [Abstract][Full Text] [Related]
17. Post-translational modification and stability of low molecular weight cyclin E.
Mull BB; Cox J; Bui T; Keyomarsi K
Oncogene; 2009 Sep; 28(35):3167-76. PubMed ID: 19561641
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of cyclin E in low-risk node negative breast cancer.
Ahlin C; Gruhne B; Holmqvist M; Zetterberg A; Fjällskog ML
Acta Oncol; 2008; 47(8):1539-45. PubMed ID: 18607847
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
20. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
